Table 4 The relationship between PD-L1 and dMMR/pMMR
Author/year | Tumor | N | PD-L1+ (%) | dMMR (%) | PD-L1+ in dMMR tumors (%) | PD-L1+ in pMMR tumors (%) | P | The impact of PD-L1 or dMMR on survival |
|---|---|---|---|---|---|---|---|---|
Gatalica Z [74] 2014 | CC | 87 | 20.7 | 31.0 | 38.0 | 13.0 | 0.02 | NA |
Inaguma S [83] 2016 | CRC | 506 | NA | NA | 44.7 | 6.8 | < 0.01 | NA |
Inaguma S [83] 2016 | GC | 180 | NA | NA | 46.7 | 12.1 | < 0.01 | NA |
Kim ST [82] 2017 | Advanced GI, GU, and others | 430 | 16.5 in all, 28.6 in melanoma, 22.4 in GC, 20.9 in CRC, 12.5 in BTC, 7.1 in GU, 6.7 in HCC, 0.0 in pancreatic cancer and sarcoma | 4.5 in all 7.1 in GC 6.7 in HCC 4.4 in CRC | 38.9 | 15.2 | < 0.01 | P = 0.535 in GC P = 0.231 in mCRC P = 0.508 in sarcoma |
Mills AM [26] 2018 | Breast carcinoma | 245 | 12.0 in all 32.0 in TNDC | 0.04 | 100.0 | NA | NA | NA |
Wang L [84] 2018 | GC | 550 | 37.3 | 8.2 | 60.0 | 35.2 | < 0.01 | NA |